Overview

The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years

Status:
Not yet recruiting

Trial end date:
2025-12-25

Target enrollment:

Participant gender:

Summary

A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of zanubrutinib, rituximab and lenalidomide (ZR2) versus rituximab combined with low-dose CHOP (R-miniCHOP) in the treatment of unfit or frail de novo diffuse large B-cell lymphoma patients aged older than or equal to 70 years

Phase:

Phase 3

Details

Lead Sponsor:

Ruijin Hospital

Treatments:

Lenalidomide
Rituximab
Zanubrutinib